2Konturek SJ. Konlurek PC, Konturek JW, et al. Helicobacter pylori and its involvement in gastritis and peptic ulcer formation.J PhysiolPharmacol, 2006,57 (Suppl 3): 29-50.
3Atherton JC. The pathugenesis of Helicobacter pylori induced gastro duodenal diseases. Annu Rev Pathol,2006,1:63-96.
4Hamajima N. Persistent Helieobacter pylori infection and genetic polymorphisms of the host. Nagoya J Med Sci, 2003, 66: 103-117.
5Dincer D, Duman A, Dikici H, et al. NSAID-related upper gastrointestinal bleeding: are risk factors considered during prophylaxis? Int J Clin Pract,2006,60 : 546-548.
6Zapata Colindres JC, Zepeda Gomez S, Montano Loza A, et al. The association of Helicobacter pylori infection and nonsteroidal anti inflammatory drugs in peptic ulcer disease. Can J Gastroenterol, 2006, 20: 277-280.
7Metz DC, Sostek MB, Ruszniewski P, et al. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol, 2007, 102:2648-2654.
8Egan BJ, Katicic M, O'Connor HJ, et al. Treatment of Helicobacter pylori. Helicobacter, 2007, 12:31-37.
9Zullo A, Rinaldi V, Winn S, et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther, 2000. 14: 715-718.
10Tanaka A, Araki H, Hase S, et al. Up regulation of COX-2 by inhibition of COX 1 in the rat: a key NSAID-induced gastric injury. Aliment Pharmacol Ther, 2002, 16(Supple) :90-101.
